ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

GNMK GenMark Diagnostics Inc

24.05
0.00 (0.00%)
14 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
GenMark Diagnostics Inc NASDAQ:GNMK NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 24.05 23.92 24.39 0 01:00:00

GenMark Diagnostics to Present at the William Blair 2014 Growth Stock Conference

06/06/2014 7:59pm

Business Wire


GenMark Diagnostics (NASDAQ:GNMK)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more GenMark Diagnostics Charts.

GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the William Blair 2014 Growth Stock Conference to be held at the Four Seasons Hotel in Chicago, IL on Wednesday, June 11, 2014. The presentation will be delivered by Hany Massarany, President and Chief Executive Officer, and is scheduled to begin at 3:20 p.m. Central Time (1:20 p.m. Pacific Time). The presentation will be made available at http://ir.genmarkdx.com/.

ABOUT GENMARK

GenMark Diagnostics is a leading provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. Utilizing GenMark's proprietary eSensorĀ® detection technology, GenMark's eSensorĀ® XT-8 system is designed to support a broad range of molecular diagnostic tests with a compact, easy-to-use workstation and self-contained, disposable test cartridges. GenMark currently markets four tests that are FDA cleared for IVD use: Cystic Fibrosis Genotyping Test, Respiratory Virus Panel, Thrombophilia Risk Test, and Warfarin Sensitivity Test. A number of other tests, including HCV Genotyping, 2C19 Genotyping, and 3A4/3A5 Genotyping are available for research use only. For more information, visit www.genmarkdx.com.

GenMark Diagnostics, Inc.Hany MassaranyPresident, Chief Executive Officer760-448-4358

1 Year GenMark Diagnostics Chart

1 Year GenMark Diagnostics Chart

1 Month GenMark Diagnostics Chart

1 Month GenMark Diagnostics Chart